Analyst firms · Oppenheimer · TDOC
Oppenheimer TDOC price target and rating history
Teladoc Health Inc. (TDOC) · Health Care
Oppenheimer rates Teladoc Health Inc. (TDOC) Outperform with a $130 price target, as of its latest action on Feb 23, 2022. It has published 4 rating actions on TDOC since July 2021, including 0 upgrades and 0 downgrades. Across 3 firms with a TDOC price target in the last 12 months, the median target is $8.50.
- Current rating
- Outperform
- Price target
- $130
- Median target, all firms
- $8.50
- Actions on TDOC
- 4
Oppenheimer price target on TDOC
Every Oppenheimer rating on TDOC
- Feb 23, 2022
- Nov 19, 2021
- Oct 28, 2021
- Jul 28, 2021
How other firms rate TDOC
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Argus Research | Sell | Nov 2, 2026 | |
| Deutsche Bank | Buy | $11 | Mar 10, 2026 |
| BofA Securities | Buy | $7 | Feb 26, 2026 |
| Barclays | Equal Weight | $8.50 | Dec 9, 2025 |
Questions about Oppenheimer and TDOC
- What is Oppenheimer's price target for TDOC?
- Oppenheimer's latest stated price target for Teladoc Health Inc. (TDOC) is $130, from its action on Feb 23, 2022.
- What is Oppenheimer's rating on TDOC?
- Oppenheimer rates TDOC Outperform, a bullish rating, as of Feb 23, 2022.
- When did Oppenheimer last change its view on TDOC?
- On Feb 23, 2022, Oppenheimer cuts its price target to $130 from $160, keeps Outperform.
- How does Oppenheimer's TDOC target compare with other analysts?
- Across 3 firms with a TDOC price target in the last 12 months, the median target is $8.50.
More TDOC rating histories
- Argus Research4
- Deutsche Bank4
- BofA Securities4
- Barclays4
- Goldman Sachs4
- Jefferies3
- Leerink Partners7
- Guggenheim4
- KeyBanc Capital Markets3
- Needham4
- Wells Fargo3
- Citigroup3
- Credit Suisse4
- Piper Sandler3
All Oppenheimer ratingsTDOC news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.